Genmab A/S Graham Number
The Graham Number of Genmab A/S (GMAB.CO) as of Oct 15, 2026 is 27.08 USD. In the previous year, Graham Number was 195.12 USD — a change of -86.12% (lower).
Get this data via API
Financial Data API
Graham Number
27.08USD
YoY
-86.12%
Last updated:
The Genmab A/S Graham Number history
3 Years
10 Years
25 Years
Max
| YEAR | Graham Number | YoY |
|---|---|---|
| 27.08USD | -86.12% | |
| 195.12USD | +47.12% | |
| 132.63USD | -3.81% | |
| 137.88USD | +49.64% | |
| 92.14USD | -15.19% | |
| 108.65USD | +71.44% | |
| 63.37USD | +57.14% | |
| 40.33USD | +32.42% | |
| 30.46USD | +7.15% | |
| 28.42USD | +45.42% | |
| 19.55USD | +104.50% | |
| 9.56USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Genmab A/S Stock analysis
Frequently Asked Questions about Genmab A/S stock
Graham Number of Genmab A/S is 27.08 USD in 2025.
On Eulerpool you can find the complete historical development of Graham Number Genmab A/S since 2006 – with annual values, charts, and detailed analysis.
The Graham Number estimates the maximum fair price for a stock based on EPS and book value per share, following Benjamin Graham's value investing principles.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Genmab A/S
All Key Metrics — Genmab A/S
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth